Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
One Percent Rule Checklist For Safer Forex Trading Risk 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
(4) - EconoTimes)
CAMBRIDGE, Mass., April 05, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted an equity award on April 3, 2017 to Catherine Stehman-Breen. The award was previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to Dr. Stehman-Breen’s employment as chief medical officer. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Dr. Stehman-Breen received options to purchase 100,000 shares of Sarepta's common stock. The options have an exercise price of $29.70 per share, which is equal to the closing price of Sarepta's common stock on April 3, 2017. One-fourth of the shares underlying the employee’s option will vest on the one year anniversary of her date of hire and thereafter 1/48th of the shares underlying the option will vest monthly, such that the shares underlying the option will be fully vested on the fourth anniversary of her date of hire, in each case, subject to her continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
